As for the overall survival (OS), upon R-CHOP treatment, TP53Mut patients showed unfavorable outcome in the Ruijin cohort (P = 0.0153), BCC cohort (P = 0.0042), and HMRN cohort (P = 0.0007), as compared to TP53WT patients (Supplementary Fig. 4a). This evidence concerns the gene DDIT3 and skin basal cell carcinoma.